Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs ASP-8374 (Primary) ; Pembrolizumab
  • Indications Prostate cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Astellas Pharma Global Development
  • Most Recent Events

    • 28 Nov 2018 Planned number of patients changed from 400 to 363.
    • 28 Nov 2018 Planned End Date changed from 1 Mar 2022 to 1 Apr 2022.
    • 28 Nov 2018 Planned primary completion date changed from 1 Mar 2022 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top